Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?

Alwena H. Morgan, Daniel J. Rees, Zane B. Andrews, Jeffrey S. Davies

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Parkinson's disease is a common age-related neurodegenerative disorder affecting 10 million people worldwide, but the mechanisms underlying its pathogenesis are still unclear. The disease is characterised by dopamine nerve cell loss in the mid-brain and intra-cellular accumulation of α-synuclein that results in motor and non-motor dysfunction. In this review, we discuss the neuroprotective effects of the stomach hormone, ghrelin, in models of Parkinson's disease. Recent findings suggest that it may modulate mitochondrial function and autophagic clearance of impaired organelle in response to changes in cellular energy balance. We consider the putative cellular mechanisms underlying ghrelin-action and the possible role of ghrelin mimetics in slowing or preventing Parkinson's disease progression.

Original languageEnglish
Pages (from-to)317-326
Number of pages10
JournalNeuropharmacology
Volume136
Issue numberPart B
DOIs
Publication statusPublished - 1 Jul 2018

Keywords

  • Dementia
  • Ghrelin
  • Parkinson's disease

Cite this